Creo Medical Group Valuation
Is CREO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CREO?
Other financial metrics that can be useful for relative valuation.
|What is CREO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CREO's PS Ratio compare to its peers?
|Company||PS||Estimated Growth||Market Cap|
IHC Inspiration Healthcare Group
YGEN Yourgene Health
SMD Spectral MD Holdings
CREO Creo Medical Group
Price-To-Sales vs Peers: CREO is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (4.4x).
Price to Earnings Ratio vs Industry
How does CREO's PE Ratio compare vs other companies in the GB Medical Equipment Industry?
Price to Sales Ratio vs Fair Ratio
What is CREO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1.4x|
|Fair PS Ratio||1.8x|
Price-To-Sales vs Fair Ratio: CREO is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).
Share Price vs Fair Value
What is the Fair Price of CREO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CREO (£0.2) is trading below our estimate of fair value (£1.1)
Significantly Below Fair Value: CREO is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.